Aktis Oncology vs GE HealthCare

Side-by-side comparison of AI visibility scores, market position, and capabilities

GE HealthCare leads in AI visibility (93 vs 67)
Aktis Oncology logo

Aktis Oncology

ChallengerHealthcare & Life Sciences

Radiopharmaceuticals

Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.

AI VisibilityBeta
Overall Score
B67
Category Rank
#1 of 1
AI Consensus
84%
Trend
up
Per Platform
ChatGPT
72
Perplexity
69
Gemini
68

About

Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.

Full profile
GE HealthCare logo

GE HealthCare

LeaderHealthcare Tech

Enterprise

Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.

AI VisibilityBeta
Overall Score
A93
Category Rank
#183 of 290
AI Consensus
61%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
95
Gemini
85

About

GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.

Full profile

AI Visibility Head-to-Head

67
Overall Score
93
#1
Category Rank
#183
84
AI Consensus
61
up
Trend
stable
72
ChatGPT
99
69
Perplexity
95
68
Gemini
85
74
Claude
84
68
Grok
89

Key Details

Category
Radiopharmaceuticals
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Aktis Oncology
Radiopharmaceuticals

Integrations

Only Aktis Oncology
GE HealthCare is classified as company (part of GE Aerospace).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.